Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Unmodified Report (Clean Opinion) by Statutory Auditors
Auditor’s Comment:
The auditors issued an unmodified review report stating that nothing came to their attention causing them to believe the statement contains any material misstatement.
Key Financial Highlights [Rs. in lacs]:
Standalone Results:
Revenue from Operations: ₹698.35 lakhs (27.4% increase from ₹548.09 lakhs in Q1 FY26)
Total Income: ₹714.00 lakhs (30.0% increase from ₹549.26 lakhs in Q1 FY26)
EBITDA: Not Specified
Net Profit: Net Loss of ₹(248.48) lakhs (improved from net loss of ₹(532.43) lakhs in Q1 FY26)
EPS: Basic and Diluted EPS of ₹(1.15) (improved from ₹(2.47) in Q1 FY26)
Other Equity: Not Specified
Cash and Cash Equivaleents: Not Specified
Debt: Not Specified
Expense Breakdown [Rs. in lacs]:
Cost of Material Consumed: ₹(0.03) lakhs
Purchase of Stock-in-Trade: ₹50.69 lakhs
Changes in Inventories: ₹(9.54) lakhs
Employee Benefits Expenses: ₹277.92 lakhs
Finance Costs: ₹188.05 lakhs
Depreciation and Amortisation: ₹158.78 lakhs
Other Expenses: ₹296.61 lakhs
Total Expenses: ₹962.48 lakhs (decreased from ₹1,081.69 lakhs in Q1 FY26)
Consolidated Results:
Not Specified - The results presented are standalone only
Segment-wise Performance:
The company operates in one segment only, hence no segment results have been disclosed.
Corporate Actions:
The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited at their meeting held on June 26, 2026. The appointed date for this scheme of amalgamation is April 1, 2026, subject to necessary consents/approvals.
No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities were announced.
Other Significant Information:
The company does not have any Subsidiary/Associate/Joint venture companies as of June 30, 2026.
The figures for the quarter ended March 31, 2026 are balancing figures between audited figures for the full financial year 2025-26 and published year-to-date reviewed figures up to December 31, 2025.
Entities:
Statutory Auditors: Bhavani & Co., Chartered Accountants (Firm Registration No: 0121398)
Review Partner: CA Kavitha Padmini (Membership no: 229966)
Company Secretary & Compliance Officer: Rakesh R Kalbate
Managing Director/CEO: Manish Kumar Jain (DIN: 06477976)